Swedish Orphan Biovitrum Logo

Swedish Orphan Biovitrum

Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.

SOBI | ST

Overview

Corporate Details

ISIN(s):
SE0000872095 (+51 more)
LEI:
549300124Y3MQI87PT35
Country:
Sweden
Address:
Tomtebodavagen 23A, 112 76 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Swedish Orphan Biovitrum (Sobi) is a global biopharmaceutical company dedicated to developing and delivering innovative therapies for people with rare and debilitating diseases. The company focuses its research, development, and commercialization efforts on treatments in the areas of haematology, immunology, and specialty care. Sobi leverages its expertise in protein biochemistry and biologics manufacturing to address significant unmet medical needs. The company is committed to improving patient lives by providing sustainable access to transformative treatments for rare disease communities worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-30 08:00
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Sobi
English 137.5 KB
2025-09-30 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Sobi
Swedish 126.9 KB
2025-08-29 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Sobi
Swedish 100.2 KB
2025-08-29 08:00
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Sobi
English 97.9 KB
2025-08-21 12:35
Share Issue/Capital Change
Sobi has completed issues of class C shares
English 151.8 KB
2025-08-21 12:35
Share Issue/Capital Change
Sobi har genomfört emissioner av C-aktier
Swedish 151.6 KB
2025-07-16 08:00
Quarterly Report
Swedish 4.1 MB
2025-07-16 08:00
Earnings Release
English 4.1 MB
2025-07-15 19:15
Share Issue/Capital Change
The Board of Directors of Sobi exercises authorisation for repurchase of shares…
English 138.4 KB
2025-07-15 19:15
Transaction in Own Shares
Sobis styrelse utnyttjar återköpsbemyndigande för säkerställande av bolagets åt…
Swedish 137.1 KB
2025-07-01 13:00
M&A Activity
Sobi uppdaterar avtalet med Apellis om royalty på Aspaveli® (systemisk pegcetac…
Swedish 193.0 KB
2025-07-01 13:00
M&A Activity
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli…
English 202.6 KB
2025-06-28 00:55
Regulatory News Service
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and…
English 227.3 KB
2025-06-28 00:55
Earnings Release
FDA godkänner Gamifant® (emapalumab-lzsg) som den första behandlingen för vuxna…
Swedish 244.4 KB
2025-05-08 11:30
Post-Annual General Meeting Information
Kommuniké från Sobis årsstämma
Swedish 148.7 KB

Automate Your Workflow. Get a real-time feed of all Swedish Orphan Biovitrum filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Swedish Orphan Biovitrum via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-30 Katy Mazibuko Other Sell 1,500 480,000.00 SEK
2024-08-30 Katy Mazibuko Other Sell 269 86,012.75 SEK
2024-08-12 Sara Karlsson Other Buy 86 23,391.79 SEK
2024-07-25 Mahmood Ladha Other Buy 84,585 12,360,406.05 SEK
2024-07-23 Mahmood Ladha Other Sell 84,585 24,614,235.00 SEK
2024-06-10 Christin Wesström Other Other 7,433 N/A
2024-06-03 Guido Oelkers Other Buy 117,332 23,965,061.00 SEK
2024-05-30 Guido Oelkers Other Sell 117,332 32,090,302.00 SEK
2024-05-15 Henrik Stenqvist Other Buy 72,534 14,815,069.50 SEK
2024-05-13 Henrik Stenqvist Other Sell 72,534 20,766,484.20 SEK

Peer Companies

Company Country Ticker View
Astena Holdings Co., Ltd. Logo
Develops and sells chemicals, pharma, and ingredients for food, cosmetic, and industrial use.
Japan 8095
AstraZeneca PLC Logo
Global biopharma developing medicines for oncology, cardiovascular, respiratory & rare diseases.
United Kingdom AZN
Bioengineering solutions to accelerate life sciences research, from gene synthesis to cell lines.
South Korea 355690
Bachem Holding AG Logo
A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.
Switzerland BANB
Basilea Pharmaceutica AG Logo
Develops & commercializes anti-infectives for severe bacterial & fungal infections.
Switzerland BSLN
Bavarian Nordic Logo
A biotech firm developing and manufacturing life-saving vaccines for travel and public health.
Denmark BAVA
Bayer AG Logo
A life science firm providing pharmaceuticals, consumer health, and crop science solutions.
Germany BAY
Benchmark Holdings Plc Logo
Aquaculture biotech providing nutrition and health solutions for sustainable farming.
United Kingdom BMK
BIFIDO. Co. Ltd Logo
Biotech firm specializing in microbiome R&D for functional foods and cosmeceuticals.
South Korea 238200
BioArctic Logo
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
Sweden BIOA

Talk to a Data Expert

Have a question? We'll get back to you promptly.